ExpreS2ion announces poster presentation on ES2B-C001 at the AACR Annual Meeting 2023

Hørsholm, Denmark, 18 April 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces that the company through its research collaboration partners at University of Bologna presented a poster on ES2B-C001, our unique HER2-VLP breast cancer vaccine candidate, at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida. The presentation poster titled “Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis” concludes, that: ES2B-C001 vaccination inhibited the onset, growth, and metastatic spread of HER-2 positive mammary carcinomas in mice. The vaccine induced strong and persistent antibody responses that inhibited human HER-2+ breast and gastric cancer cells in vitro. ES2B-C001 is a promising candidate vaccine for the therapy of human tumours expressing HER-2. Preclinical results warrant further development towards human clinical studies. A copy of the poster can be found at the company webpage at https://expres2ionbio.com/meet-us/ Certified Adviser Svensk Kapitalmarknadsgranskning AB For further information about ExpreS2ion Biotech Holding AB, please contact: Bent U. Frandsen, CEO Telephone: +45 4256 6869 E-mail: [email protected] Keith Alexander, CFO Telephone: +45 5131 8147 E-mail: [email protected]  About ExpreS2ion ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com. Attachments 230418 EXPRS2 AACR Poster Presentation

The release as fetched from its publisher. expres2ionbio.com ↗